SNT.WAR Synektik S.A.
- Market cap
- PLN 2.84B
- P/E
- 16.0x
- P/B
- 13.16x
- ROE
- 328.2%
- Dividend yield
- 2.48%
- Fundamental score
- 3.8/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is SNT.WAR undervalued?
Graham numberThe Graham number of Synektik S.A. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Synektik S.A. fundamental analysis
17 of 22 checks passedROE 2/2
High return on equity (328.2%), above 20%.
ROA 1/1
Return on assets (124.2%) is above the industry median (-6.0%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (20.9%) is not above the 5-year average (63.3% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (20.9%) is below the industry median (24.1%).
Revenue Growth 2/2
Revenue grew 59.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (19.4%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE (16.0x) is above the market median (11.6x).
PE vs Industry 1/1
PE (16.0x) is below the industry median (16.1x).
PBV 0/1
Price to book (13.2x) is above the industry median (3.4x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 210.9, limit 22.5).
PEG 1/1
PEG on 5-year earnings growth is 0.25, growth is cheap.
Dividend Yield 1/2
Dividend yield (2.5%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 8 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 68.9%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Synektik S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Synektik S.A.
Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics for oncology. In addition, it offers maintenance services for medical equipment,…
Full company profileSynektik S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Synektik S.A. annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 49.4M | 62.9M | 105M | 135M | 125M | 129M | 167M | 447M | 624M | 681M | 1.01B |
| Gross Profit | 10.5M | 14.5M | 23.7M | 32.6M | 30.7M | 30.3M | 48.5M | 132M | 190M | 243M | 346M |
| Operating Income | 2.13M | 3.57M | 11.6M | 12.7M | 12.0M | 11.2M | 7.04M | 67.9M | 107M | 157M | 240M |
| EBITDA | 4.35M | 7.92M | 15.8M | 17.7M | 18.5M | 18.7M | 25.8M | 82.4M | 122M | 179M | 263M |
| Net Income | 388K | 4.09M | 10.3M | 9.14M | 8.81M | 8.38M | 10.3M | 52.5M | 84.6M | 102M | 703M |
| EPS | 0.05 | 0.48 | 1.21 | 1.07 | 1.03 | 0.98 | 1.21 | 6.15 | 9.92 | 12 | 82 |
| Balance Sheet | |||||||||||
| Total Assets | 90.8M | 115M | 109M | 125M | 142M | 160M | 236M | 300M | 375M | 487M | 566M |
| Total Liabilities | 33.8M | 53.5M | 46.6M | 54.8M | 65.6M | 79.1M | 149M | 166M | 185M | 264M | 352M |
| Shareholders' Equity | 56.9M | 61.7M | 62.0M | 70.3M | 76.0M | 80.6M | 87.8M | 134M | 190M | 223M | 214M |
| Cash & Short-term Investments | 8.08M | 19.5M | 5.29M | 8.55M | 10.9M | 18.3M | 10.9M | 63.5M | 84.3M | 84.3M | 78.7M |
| Total Debt | 5.72M | 3.27M | 16.2M | 12.2M | 20.6M | 18.2M | 36.9M | 18.7M | 24.5M | 40.2M | 41.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.06M | 14.6M | 5.22M | 13.5M | 13.9M | 21.7M | -6.18M | 94.5M | 89.6M | 77.7M | 86.2M |
| Capital Expenditure | 6.98M | 6.69M | 2.37M | 5.51M | 5.11M | 3.43M | 10.2M | 8.29M | 44.9M | 18.1M | 29.4M |
| Free Cash Flow | -15.0M | 7.88M | 2.85M | 8.03M | 8.81M | 18.3M | -16.4M | 84.8M | 44.7M | 59.6M | 56.7M |
| Ratios | |||||||||||
| ROE | 0.7% | 6.6% | 16.6% | 13.0% | 11.6% | 10.4% | 11.7% | 39.1% | 44.5% | 45.9% | 328.2% |
| ROA | 0.4% | 3.5% | 9.5% | 7.3% | 6.2% | 5.3% | 4.4% | 17.5% | 22.6% | 21.0% | 124.2% |
| Net Profit Margin | 0.8% | 6.5% | 9.8% | 6.8% | 7.0% | 6.5% | 6.2% | 11.7% | 13.6% | 15.0% | 69.5% |
| Debt to Equity | 0.10x | 0.05x | 0.26x | 0.17x | 0.27x | 0.23x | 0.42x | 0.14x | 0.13x | 0.18x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Synektik S.A. dividends
- Dividend yield
- 2.48%
- Forward dividend
- 10.75 PLN
- Payout ratio
- 68.9%
- Ex-dividend date
- Jan 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | PLN 70.4M | 8.26 | 68.9% |
| 2024 | PLN 25.8M | 3.03 | 30.5% |
| 2023 | PLN 5.12M | 0.60 | 9.8% |
| 2022 | PLN 3.84M | 0.45 | 37.3% |
| 2021 | PLN 3.84M | 0.45 | 45.8% |
| 2020 | PLN 3.07M | 0.36 | 34.9% |
| 2019 | PLN 3.07M | 0.36 | 33.6% |
| 2018 | PLN 3.07M | 0.36 | 29.8% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Synektik S.A.
- Insiders 16.79%
- Institutions 17.74%
- Public & others 65.46%
- Shares outstanding 8.53M
- Free float 7.00M
Synektik S.A. company profile
- Company name
- Synektik S.A.
- Ticker
- SNT.WAR
- ISIN
- PLSNKTK00019
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 231
- Fiscal year end
- December
- Address
- ul. JOzefa Piusa Dziekonskiego 3, Warsaw, Poland, 00-728
- Phone
- 48 22 327 0900
- Website
- synektik.com.pl
About Synektik S.A.
Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics for oncology. In addition, it offers maintenance services for medical equipment, as well as acceptance and specialist tests. The company was founded in 2001 and is based in Warsaw, Poland.
Synektik S.A. management
8- Mr. Cezary Dariusz KozaneckiPresident of the Management Board & MD
- Mr. Dariusz Marcin KoreckiVice President of the Management Board
- Ms. Sawa Zuzanna ZarebinskaSecretary & Member of the Supervisory Board
- Mr. Tomasz WróbelMember of the Management Board
- Ms. Katarzyna DebowskaChief Accountant
- Mr. Piotr KaszubaHead of Technology Laboratory and Laboratory Technical Manager
- Mr. Jacek KrusDeputy Administrative Director
- Mr. Waldemar Wojciech MagnuszewskiSales Director